XNAS
SHOTW
Market cap645kUSD
Jun 10, Last price
0.02USD
Name
Jupiter Wellness Inc
Chart & Performance
P/E
—
P/S
0.92
EPS
—
Div Yield, %
—
Shrs. gr., 5y
48.19%
Rev. gr., 5y
155.44%
Revenues
702k
+246.36%
Net income
-49m
L+227.58%
CFO
-19m
L+88.73%
Earnings
Aug 12, 2025
Profile
Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. The company's clinical pipeline includes CaniDermRX (JW-100), a novel topical formulation containing CBD and aspartame for the treatment of eczema, dermatitis, and actinic keratosis; JW-101, a prescription product for the treatment of burns; and JW-200, a non-prescription lotion/lip balm for the treatment of symptoms of cold sores. It also manufactures, distributes, and markets a line of consumer products, such as CBD-infused sunscreen under the CaniSun brand; CBD-infused skin care lotion under the CaniSkin brand; and products for the dermatological treatments of pain and inflammation under the CaniDermRX brand. The company was formerly known as CBD Brands, Inc. Jupiter Wellness, Inc. was incorporated in 2018 and is headquartered in Jupiter, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 702 246.36% | 203 -96.73% | 6,197 115.44% | ||||
Cost of revenue | 42,760 | 12,180 | 17,687 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (42,058) | (11,977) | (11,490) | ||||
NOPBT Margin | |||||||
Operating Taxes | 2,448 | ||||||
Tax Rate | |||||||
NOPAT | (42,058) | (11,977) | (13,938) | ||||
Net income | (49,410) 227.58% | (15,083) -14.65% | (17,671) -40.77% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 14,588 | 13,457 | (2,603) | ||||
BB yield | -200.64% | -33.27% | |||||
| Debt | |||||||
Debt current | 5,511 | 1,764 | 2,212 | ||||
Long-term debt | 441 | 825 | 1,203 | ||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | 5,321 | (2,745) | (1,433) | ||||
| Cash flow | |||||||
Cash from operating activities | (19,088) | (10,114) | (6,396) | ||||
CAPEX | (86) | (2,306) | (15) | ||||
Cash from investing activities | (5) | (330) | (2,472) | ||||
Cash from financing activities | 15,608 | 12,800 | (956) | ||||
FCF | (40,104) | (9,139) | (16,699) | ||||
| Balance | |||||||
Cash | 632 | 5,334 | 4,848 | ||||
Long term investments | |||||||
Excess cash | 596 | 5,323 | 4,539 | ||||
Stockholders' equity | (115,028) | (64,910) | (50,575) | ||||
Invested Capital | 118,480 | 75,796 | 56,972 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 55,931 | 30,878 | 22,107 | ||||
Price | 0.13 -90.08% | 1.31 | |||||
Market cap | 7,271 -82.03% | 40,453 | |||||
EV | 12,592 | 37,708 | |||||
EBITDA | (41,629) | (11,763) | (10,969) | ||||
EV/EBITDA | |||||||
Interest | 176 | 171 | 1,286 | ||||
Interest/NOPBT | |||||||